A report published in the March issue of the International Society for Pharmacoeconomics and Outcomes Research’s Value in Health suggests real-world evidence has limited use in pharmacy and therapeutic committee decisions.
The report took into account perspectives from pharmacists and physicians “employed by managed care organizations, pharmacy benefit managers, healthcare systems and government agencies,” according to ISPOR.
As part of a two-phase investigation, the participants took an online survey involving potential RWE uses and engaged in focus groups or telephone interviews regarding the general attitude toward uses of RWE.
According to the report, participants gave the following responses when asked whether their organizations use observational studies when deciding on use of medication:
- 11 percent said almost never;
- 79 percent said sometimes;
- 5 percent said often; and
- 5 percent said almost always.
“Heretofore, little has been known about how managed care organizations use real-world evidence in their formulary, utilization management, drug monographs, and other decision-making processes,” lead author Daniel Malone, of University of Arizona, says. “This study provides new insight that can be used to improve both the quantity and quality of real-world evidence as it is applied to the healthcare decision making process.”